Amgen announced that the Journal of Clinical Oncology published results from the Phase 2, open-label ALCANTARA study evaluating the efficacy and safety of Blincyto (blinatumomab) in patients with Philadelphia chromosome-positive relapsed or refractory B-cell precursor acute lymphoblastic leukemia who had failed at least one second-generation or later tyrosine kinase inhibitor.
Eli Lilly and Co. said that following a pre-planned interim analysis for MONARCH 3, the trial met its primary endpoint of demonstrating statistically significant improvement in progression-free survival. In addition, improvement was shown in a key secondary endpoint of objective response rate.
FDA granted an accelerated approval to Bavencio (avelumab) for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
In a simple definition, cancer is a disease of the cells, which is caused by gene mutations. For a proportion of patients, including women with hormone receptor positive breast cancer, gene expression profiling has a substantial impact on treatment decision-making by determining which patients might—or might not—respond to particular treatment options.
Researchers led by St. Jude Children's Research Hospital scientists have worked out how a crucial cancer-related protein, a "histone writer" called Ezh2, plays a role in suppressing as well as driving the most aggressive form of the brain tumor medulloblastoma.
OncoGenex Pharmaceuticals Inc. said apatorsen results from two randomized phase II clinical trials were presented at the American Society of Clinical Oncology 2017 Genitourinary Cancers Symposium.
A new study offers a treatment option for patients with recurrent lung cancer, who historically have been considered ineligible for curative treatment.
AstraZeneca presented data from the confirmatory Phase III SOLO-2 trial demonstrating a statistically significant and clinically meaningful improvement of progression-free survival among patients treated with Lynparza (olaparib) compared to placebo.
Eli Lilly and Co. said its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival. The phase III study evaluated abemaciclib, a cyclin-dependent kinase 4 and CDK 6 inhibitor, in combination with fulvestrant in women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer who have relapsed or progressed after endocrine therapy.
